PRQR
HOLD / NEUTRALMeanRevComposite
45.50
Technical
86.30
Fundamental
31.90
Rank
—
Price
2.27
Hurst
0.20
As of
Aug 21, 2026
Daily
ProQR Therapeutics N.V.
HealthcareBiotechnologyProQR Therapeutics N.V. is a clinical-stage biotech company developing RNA editing treatments for genetic disorders using its Axiomer platform technology. The company's pipeline includes candidates targeting cholestatic diseases, Rett syndrome, metabolic liver disease, and cardiovascular conditions, with a research partnership with Eli Lilly focused on liver and nervous system disorders. Founded in 2012 and based in the Netherlands, ProQR aims to address genetic diseases with limited existing treatment options.
Market cap
$266.7M
P/E (trailing)
—
P/E (forward)
-4.00
PEG ratio
—
Dividend yield
—
Beta
0.06
52w range
1.33 – 3.10
Return on equity
-57.40%
Profit margin
-228.18%
Revenue growth
+120.40%
Earnings growth
—
Price history
1Y: 1.89 (-13.7%) · range 1.37–3.05
Cycle position
37/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 49 · WEAK SETUP · exit proximity 0
Conviction
26/ 100 · maturity 100%
VScore.406
Buildup.2034
EMA entry setup.2549
Fundamentals.1532
Volume profile
POC
1.76
Price vs POC
+7.3%
Overhead supply
27%
Runway
open sky
Value area 1.48–1.95 · 27% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.300 | Sep 3, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -20.51% | +3.85% | 14/20d |
| 40d | -20.51% | +3.85% | 14/40d |